These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37674501)

  • 1. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape.
    Murthy SK; Weizman AV; Kuenzig ME; Windsor JW; Kaplan GG; Benchimol EI; Bernstein CN; Bitton A; Coward S; Jones JL; Lee K; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Sabrie N; Gupta S; Brar G; Khan R; Im JHB; Davis T; Weinstein J; St-Pierre J; Chis R; Meka S; Cheah E; Goddard Q; Gorospe J; Kerr J; Beaudion KD; Patel A; Russo S; Blyth J; Blyth S; Charron-Bishop D; Targownik LE
    J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S97-S110. PubMed ID: 37674501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors.
    Nguyen GC; Targownik LE; Singh H; Benchimol EI; Bitton A; Murthy SK; Bernstein CN; Lee K; Cooke-Lauder J; Kaplan GG
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S68-S72. PubMed ID: 31294386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
    Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars in inflammatory bowel disease.
    Talathi S; Baig KRKK
    J Dig Dis; 2020 Nov; 21(11):610-620. PubMed ID: 32920972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data on the infliximab biosimilar CT-P13 (Remsima
    Huguet JM; Cortés X; Bosca-Watts MM; Aguas M; Maroto N; Martí L; Amorós C; Paredes JM
    World J Clin Cases; 2021 Dec; 9(36):11285-11299. PubMed ID: 35071559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs.
    Kuenzig ME; Coward S; Targownik LE; Murthy SK; Benchimol EI; Windsor JW; Bernstein CN; Bitton A; Jones JL; Lee K; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Im JHB; Jogendran R; Meka S; Weinstein J; Jones May T; Jogendran M; Tabatabavakili S; Hazan E; Hu M; Osei JA; Khan R; Wang G; Browne M; Davis T; Goddard Q; Gorospe J; Latos K; Mason K; Kerr J; Balche N; Sklar A; Kaplan GG
    J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S23-S34. PubMed ID: 37674493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.
    Shaffer SR; Kuenzig ME; Windsor JW; Bitton A; Jones JL; Lee K; Murthy SK; Targownik LE; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Tandon P; St-Pierre J; Natt N; Davis T; Weinstein J; Im JHB; Benchimol EI; Kaplan GG; Goddard Q; Gorospe J; Bergevin M; Silver K; Bowles D; Stewart M; Pearlstein M; Dawson EH; Bernstein CN
    J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S45-S54. PubMed ID: 37674503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory bowel disease surgery in the biologic era.
    Ferrari L; Krane MK; Fichera A
    World J Gastrointest Surg; 2016 May; 8(5):363-70. PubMed ID: 27231514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
    Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
    Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
    Gold SL; Steinlauf AF
    Gastroenterol Hepatol (N Y); 2021 Sep; 17(9):406-414. PubMed ID: 34602905
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches.
    Privitera G; Pugliese D; Lopetuso LR; Scaldaferri F; Neri M; Guidi L; Gasbarrini A; Armuzzi A
    Therap Adv Gastroenterol; 2021; 14():17562848211006669. PubMed ID: 33995579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.